SCHEMBL2226680

SCHEMBL2226680

Cc1ccc(Cl)nc1C=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.35
CYP2C19 P33261 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
ALDH1A1 P00352 7/20 0.33
KDM4E B2RXH2 5/20 0.33
MAPT P10636 4/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
GAA P10253 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MPI P34949 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
POLB P06746 1/20 0.33
RECQL P46063 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
GLA P06280 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 2/20 0.32
NOS3 P29474 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29952500 1.00 CYP3A4 (0.35) CYP3A4CYP2C19CYP1A2CYP2D6ALDH1A1
SCHEMBL15595934 0.78 NOS3 (0.32) NOS3NOS1NOS2
SCHEMBL2654910 0.77 CRHBP (0.39) CYP3A4ALDH1A1KDM4EMEN1KMT2A
SCHEMBL6627151 0.77 ALDH1A1 (0.39) CYP1A2ALDH1A1KDM4EKMT2ATSHR
SCHEMBL17315652 0.76 ERN1 (0.31) CYP3A4ALDH1A1KDM4EMEN1KMT2A
SCHEMBL31337139 0.74 ALDH1A1 (0.32) ALDH1A1TSHRHTR2BCYP2A6
SCHEMBL22342564 0.74 ALDH1A1 (0.32) ALDH1A1TSHRHTR2BCYP2A6
SCHEMBL20268024 0.74 HSD17B10 (0.34) CYP3A4ALDH1A1KDM4EGAAL3MBTL1
SCHEMBL1321340 0.74 RRM2 (0.45) CYP3A4CYP2C19CYP1A2ALDH1A1KDM4E
SCHEMBL29736642 0.74 HSD17B10 (0.34) CYP3A4ALDH1A1KDM4EGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4554680-A1 INHIBITORS OF HPK1 AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2025-05-21 EP disclosed
US-20240124490-A1 INHIBITORS OF HPK1 AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2024-04-18 US disclosed
WO-2024015251-A1 INHIBITORS OF HPK1 AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2024-01-18 WO disclosed
CN-104334540-B Dimethyl-benzoic acid compounds ELI LILLY AND CO. (US) 2016-03-16 CN disclosed
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
CN-104334540-A Dimethyl-Benzoic acid compounds LILLY CO ELI 2015-02-04 CN disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed
CN-102812022-A Thiazole and oxazole kinase inhibitors AB SCIENCE 2012-12-05 CN disclosed
EP-2523952-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB Science (FR) 2012-11-21 EP disclosed
WO-2011086085-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2011-07-21 WO disclosed
EP-0946546-B1 PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE PF MEDICAMENT (FR) 2003-06-25 EP disclosed
CN-1098263-C Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine PF MEDICAMENT (FR) 2003-01-08 CN disclosed
US-6020345-A Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine PIERRE FABRE MEDICAMENT (FR) 2000-02-01 US disclosed
CN-1242772-A Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine PF MEDICAMENT (FR) 2000-01-26 CN disclosed
EP-0946546-A1 PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE PIERRE FABRE MEDICAMENT (FR) 1999-10-06 EP disclosed
WO-1998022459-A1 PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE PIERRE FABRE MEDICAMENT (FR) 1998-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SYK, LTK, MERTK CYP3A4 2940/4885CYP2C19 2894/4885CYP1A2 3569/4885
US-20240124490-A1 INHIBITORS OF HPK1 AND METHODS OF USE THEREOF PHKG1, HIPK1, PHKG2 CYP3A4 3988/4885CYP2C19 3903/4885CYP1A2 3818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.